SLC5A2 and type 2 diabetes mellitus: The renoprotective and cardioprotective effects of SGLT-2 inhibitors have been established by large clinical trials in type 2 diabetes patients [10–12]; however, the beneficial effects of these medications still need to be studied in solid organ transplant recipients.